Back to All Collaborations

Novartis Access

Active Since: 2015

Access Accelerated

Contributing to SDGs…

Improving the prevention, treatment and care for noncommunicable diseases (NCDs) in lower-income countries.



  • Academia or research institute

    Boston University

    Duke NUS Medical School (Duke-NUS)

  • Global NGOs

    Management Sciences for Health (MSH)

    Tropical Health and Education (THET)

    World Heart Federation

  • Hospitals/Health Facilities

    Kenyatta National Hospital

  • Local NGOs

    American Cancer Society

    Uganda Protestant Bureau (UPB)

    Uganda Heart Institute (UHI)

    Kenya Red Cross

    Kenya Conference of Catholic Bishops and Christian Health Association Kenya (faith-based organisations)

    Christian Health Association of Kenya

    Cameroun Baptist Convention (CBC)

    Mission for Essential Drugs and Supplies (MEDS)

  • Professional and trade associations

    American Society for Clinical Pathology

    World Heart Federation


  • To improve prevention, treatment and care for noncommunicable diseases (NCDs) in lower-income countries.

What are the health needs and challenges?

Approximately 31 million people die each year from chronic non-communicable diseases (NCDs) in low– and middle–income countries, representing 80% of deaths from NCDs globally.

Partnership activities and how they address needs and challenges

The Novartis Access program makes available a portfolio of 15 critical chronic disease medicines to treat type 2 diabetes, cardiovascular diseases, respiratory illnesses, and breast cancer. These medicines are offered as a basket to governments, non-governmental organizations (NGOs) and other public-sector healthcare providers for USD 1 per treatment, per month. The aim is to make this innovative approach commercially sustainable over time, enabling continuous support in those regions.

Beyond the portfolio, we work with partners on the ground to offer capacity-building activities to support healthcare systems in preventing, diagnosing and treating chronic diseases.

We partner with organizations in four areas: community awareness and linkages to care, healthcare system strengthening, distribution and supply chain integrity, and advocacy and policy. These collaborations support the healthcare system through measures such as reinforcing drug distribution channels and training healthcare workers to diagnose and treat chronic illnesses. Novartis is also collaborating with Boston University in the US to evaluate the impact of Novartis Access in Kenya and steer ongoing development of Novartis Access.


SDG 3: Good Health and Wellbeing

  1. 3.4: NCDs (including mental health)
  2. 3.C: Health workforce

SDG 9: Industry Innovation and Infrastructure

SDG 10: Reduced Inequalities

SDG 17: Partnerships for the Goals 


Since launch in 2015, Novartis Access has delivered more than 3 million monthly treatments to five countries (Cameroon, Ethiopia, Kenya, Rwanda and Uganda), and has signed agreements for 2019 implementation in Colombia, El Salvador, Pakistan and Nigeria.